1983 – BEGINNING OF A FIRST COOPERATION
The first comprehensive interdisciplinary collaboration took place between 1983 and 1989. During this collaboration, the participants of the German-Austrian Glioma Study recognized the resulting benefits of a collaboration on various topics in neuro-oncology.
1987 – FOUNDATION
As a result, they founded the NOA in 1987 in Würzburg as a working group of the German Cancer Society.
End of the 90s – MAIN FOCUS OF WORK
Since the end of the 1990s, in addition to the structuring of interdisciplinary collaboration, the development and implementation of clinical studies and the preparation of guidelines have been the main focus of work.
2007 – GERMAN CANCER AWARD
In the category “Tumor Diagnostics and Tumor Treatment (Clinical Part)”, Prof. Dr. Michael Weller (Tübingen, now Zurich) was honored.
2008 – 300 MEMBERS
As of 2008, the NOA has over 300 members from the major disciplines of neurology, neurosurgery, radiotherapy, neuropathology, neuroradiology, and medical oncology. In addition, biostatisticians, computer scientists, neuropsychologists and some pediatric oncologists are represented.
2013 – GERMAN CANCER AWARD
Prof. Dr. Stefan Pfister (Heidelberg) was honored in the category “Translational Research”.
2015 – GERMAN CANCER AWARD
Prof. Dr. Wolfgang Wick (Heidelberg) was honored in the category “Translational Research”.
2016 – GERMAN CANCER AWARD
Prof. Dr. Andreas von Deimling (Heidelberg University Hospital) was honored in the category “Translational Research”.
2017 – GERMAN CANCER AWARD
Prof. Dr. Guido Reifenberger (Institute of Neuropathology, Heinrich Heine University Düsseldorf) was honored in the category “Translational Research”.
2019 – GERMAN CANCER AWARD
In the category “Clinical Research”, this year’s award went to Prof. Dr. Michael Platten (German Cancer Research Center, Heidelberg; University Medical Center Mannheim).
2022 – GERMAN CANCER AWARD
Prof. Dr. Frank Winkler was honored in the category “Translational Research” for the discovery of tumor networks as a possible cause of therapy resistance in brain tumors.
In addition to the study activities, the NOA acts as a scientific platform and educational tool for the German neuro-oncology community through the annual meetings and the Winter School Neuro-oncology.
In addition, due to the encouraging development in clinical and translational neuro-oncological research and the need for large clinical trials, the NOA has made itself available as a collaborating group for multinational clinical research activities. A first example is the multinational study on the treatment of 1p/19q non-co-deleted anaplastic gliomas (EORTC 26053/CATNON).
Furthermore, as a representative of the field of neuro-oncology, the NOA is involved in dealing with health policy issues. It also serves as a contact for patient and family organizations.
Established:
In preparation:
